Comfoderm M2 cream, 30g

Composition

>

of 100 g of cream contains:

Active ingredients: methylprednisolone aceponate 100 mg; urea 2 g;

Auxiliary substances: liquid paraffin (petroleum jelly oil) – 15 g, propylene glycol-5 g, polysorbate 80-1 g, carbomer interpolymer (type A) – 1 g, trometamol-400 mg, methyl parahydroxybenzoate-100 mg, purified water – up to 100 g.

Pharmacological action

A drug with anti-inflammatory and keratolytic effects for external use.

Indications

Inflammatory skin diseases that are sensitive to topical corticosteroid therapy and are accompanied by a violation of keratinization:

— atopic dermatitis, neurodermatitis;

– true eczema

— – microbial eczema—

– simple contact dermatitis—

– allergic (contact) dermatitis—

– dyshidrotic eczema.

Contraindications

-hypersensitivity to the components of the drug;

– tuberculosis or syphilitic processes in the area of application of the drug;

– viral diseases (for example, chickenpox, shingles);

– rosacea, perioral dermatitis in the area of application of the drug;

– skin areas with reactions to vaccination;

– children under 18 years of age.

Side effects

Very rarely (less than 0.01% of cases), local reactions may occur, such as itching, burning, erythema, and vesicular rash formation.

If the drug is used for more than 4 weeks and/or on an area of 10% or more of the body surface, the following reactions may occur: skin atrophy, telangiectasia, striae, acne-like skin changes, systemic effects due to corticosteroid absorption.

In rare cases (0.01%-0.1%) may have folliculitis, hypertrichosis, perioral dermatitis, skin depigmentation, allergic reactions to one of the components of the drug.

Interaction

Interaction of the drug with other medicinal products has not been revealed, however, it should be borne in mind that the simultaneous use of Comfoderm® M2 with other ointments or creams may lead to increased resorption of their constituent medicinal substances.

How to take, course of use and dosage

Externally.

The drug is applied 1 time / day in a thin layer on the affected skin areas. As a general rule, the duration of continuous daily treatment with Comfoderm® M2 should not exceed 12 weeks. When treating patients with facial skin lesions, the course of treatment should not exceed 5 days.

Overdose

Symptoms:  skin atrophy (thinning of the skin, telangiectasia, striae) may develop with excessively long and/or intensive topical application of corticosteroids.

Treatment:  if signs of skin atrophy appear, the drug should be discontinued.

Special instructions

In the presence of bacterial complications and/or dermatomycosis, in addition to therapy with Comfoderm® M2, specific antibacterial and / or antifungal treatment should be performed.

The drug is not intended for use in ophthalmology. Avoid contact with the eyes and mucous membranes.

As with the use of systemic glucocorticoids, external use of corticosteroids can lead to glaucoma (for example, after applying high doses, due to very long-term use, the use of occlusive dressings or application to the skin around the eyes). On the skin of the face, more often than on other body surfaces, after long-term treatment with corticosteroids for external use, atrophic changes may develop.

Influence on the ability to drive motor vehicles and manage mechanisms

Not detected.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 25°C.

Shelf

life is 2 years.

Active ingredient

Methylprednisolone aceponate, Urea

Dosage form

cream